KDEV Karolinska Development AB

Karolinska Development Annual Report 2024 published

Karolinska Development Annual Report 2024 published

STOCKHOLM, SWEDEN – March 21, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces publication of its Annual Report 2024.

The report is now available to download at

For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB

Phone: 2, e-mail:

Hans-Christoffer “HC” Toll, CFO, Karolinska Development AB

Phone: +46 70 717 00 41, e-mail:

TO THE EDITORS

About Karolinska Development AB



Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has a portfolio of eleven companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit

Attachments



EN
21/03/2025

Underlying

KDEVKarolinska Development AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Karolinska Development AB

 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Development’s portfolio company OssDsign raises approximate...

Karolinska Development’s portfolio company OssDsign raises approximately SEK 158 million, announces an updated strategy and revises financial targets STOCKHOLM, SWEDEN, June 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has carried out a directed share issue through an accelerated bookbuilding procedure that brought the company approximately SEK 158 million. In connection with the directed share issue, the company announced an updated strategy and revised its financial targets for the period 2025–2028. Investors in the directed is...

June 4, 2025 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Developments portföljbolag OssDsign genomför riktad nyemiss...

Karolinska Developments portföljbolag OssDsign genomför riktad nyemission om cirka 158 miljoner SEK, uppdaterar strategi och reviderar finansiella mål STOCKHOLM, 4 juni 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget OssDsign har genomfört en riktad nyemission genom ett accelererat bookbuilding-förfarande som inbringade bolaget cirka 158 miljoner kronor före transaktionskostnader. I samband med detta meddelade OssDsign en uppdaterad strategi samt reviderade sina finansiella mål inför perioden 2025–2028. Investerare i den riktade emissionen innefattar s...

June 4, 2025 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Development’s portfolio company Umecrine Cognition resumes ...

Karolinska Development’s portfolio company Umecrine Cognition resumes patient inclusion in its Phase 1b/2a clinical study STOCKHOLM, SWEDEN – May 26, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has resumed the inclusion of patients to the clinical phase 1b/2a trial evaluating the drug candidate golexanolone in PBC patients. In March, Umecrine Cognition announced that the study had been halted due to technical issues in the production of capsules used in the study, which, however, had no impact on patient safety. Ume...

May 26, 2025 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Developments portföljbolag Umecrine Cognition återupptar pa...

Karolinska Developments portföljbolag Umecrine Cognition återupptar patientrekrytering till klinisk fas 1b/2a-studie STOCKHOLM, 26 maj 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition har återupptagit inkluderingen av patienter till den kliniska fas 1b/2a-studien av golexanolon i patienter med primär biliär kolangit, PBC. Umecrine Cognition meddelade i mars att studien tillfälligt stoppats på grund av tekniska problem i produktionen av de kapslar som används i studien, något som dock inte påverkade patientsäkerheten. Umecrine Cognitio...

May 26, 2025 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Development’s Annual General Meeting 2025

Karolinska Development’s Annual General Meeting 2025 STOCKHOLM, SWEDEN – May 15, 2025. Karolinska Development AB (publ) (“Karolinska Development” or the “Company”) held the Annual General Meeting on May 15, 2025. The shareholders have had the right to exercise their voting rights in advance through postal voting pursuant to item 13 in the articles of association. Therefore, shareholders have had the choice to exercise their voting rights at the AGM by attending in person, by postal voting or through a proxy. The following resolutions were passed by the shareholders at the Annual General Mee...

May 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch